BRPI0501037A - uso de crotamina, kit e composição - Google Patents

uso de crotamina, kit e composição

Info

Publication number
BRPI0501037A
BRPI0501037A BRPI0501037-3A BRPI0501037A BRPI0501037A BR PI0501037 A BRPI0501037 A BR PI0501037A BR PI0501037 A BRPI0501037 A BR PI0501037A BR PI0501037 A BRPI0501037 A BR PI0501037A
Authority
BR
Brazil
Prior art keywords
crotamine
kit
composition
cell
genetic material
Prior art date
Application number
BRPI0501037-3A
Other languages
English (en)
Inventor
Tetsuo Yamane
Irina Kerkis
Alexandre Kerkis
Gandhi Radis Baptista
Mirian Akemi Furuie Hayashi
Katsuhiro Konno
Alvaro Rossan B P Da Silva
Lygia Da Veiga Pereira
Eduardo Brandt De Oliveira
Original Assignee
Fundacao De Amparo A Pesquisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao De Amparo A Pesquisa filed Critical Fundacao De Amparo A Pesquisa
Priority to BRPI0501037A priority Critical patent/BRPI0501037B8/pt
Priority to PCT/BR2006/000052 priority patent/WO2006096953A1/en
Priority to EP06721611.9A priority patent/EP1866332B1/en
Publication of BRPI0501037A publication Critical patent/BRPI0501037A/pt
Priority to US11/902,064 priority patent/US8278265B2/en
Publication of BRPI0501037B1 publication Critical patent/BRPI0501037B1/pt
Publication of BRPI0501037B8 publication Critical patent/BRPI0501037B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"USO DE CROTAMINA, KIT E COMPOSIçãO". A presente invenção refere-se a usos de crotamina e de composições que a contêm, baseado na sua característica de interação com material genético. Constata-se que em quantidades sub-micromolares o polipeptídeo deixa de ser tóxico, associando as características de penetração celular, condução de moléculas para a superfície, citoplasma ou núcleo celular e, de forma particular, de penetração celular seletiva. A invenção se refere ainda a composições que compreendem uma concentração farmaceuticamente eficaz de crotamina, e uso destas no tratamento de doenças e disfunções, baseado nas suas características de interação com material genético, por exemplo, DNA e RNA, e de seletividade celular.
BRPI0501037A 2005-03-18 2005-03-18 uso de crotamina e composição BRPI0501037B8 (pt)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BRPI0501037A BRPI0501037B8 (pt) 2005-03-18 2005-03-18 uso de crotamina e composição
PCT/BR2006/000052 WO2006096953A1 (en) 2005-03-18 2006-03-17 Use of crotamine, kit and composition
EP06721611.9A EP1866332B1 (en) 2005-03-18 2006-03-17 Use of Crotamine and Composition
US11/902,064 US8278265B2 (en) 2005-03-18 2007-09-18 Methods, kits and compositions comprising crotamine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0501037A BRPI0501037B8 (pt) 2005-03-18 2005-03-18 uso de crotamina e composição

Publications (3)

Publication Number Publication Date
BRPI0501037A true BRPI0501037A (pt) 2006-10-31
BRPI0501037B1 BRPI0501037B1 (pt) 2019-05-07
BRPI0501037B8 BRPI0501037B8 (pt) 2021-07-27

Family

ID=36991221

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0501037A BRPI0501037B8 (pt) 2005-03-18 2005-03-18 uso de crotamina e composição

Country Status (4)

Country Link
US (1) US8278265B2 (pt)
EP (1) EP1866332B1 (pt)
BR (1) BRPI0501037B8 (pt)
WO (1) WO2006096953A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090584A1 (en) * 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
WO2018152602A1 (pt) * 2017-02-24 2018-08-30 Fundação Oswaldo Cruz Combinação, composição farmacêutica, medicamento, método para tratar leishmaniose, e, uso da composição

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774318A (en) 1985-11-22 1988-09-27 Oncogen Snake venom growth arresting peptide
US4731439A (en) * 1985-11-22 1988-03-15 Oncogen Snake venom growth arresting peptide
US5053492A (en) * 1986-08-07 1991-10-01 Board Of Regents, The University Of Texas System Immunopurification using monoclonal antibodies to Mojave toxin
US5164196A (en) * 1987-05-19 1992-11-17 Ventech Research, Inc. Crotoxin complex as cytotoxic agent
US5232911A (en) * 1990-01-03 1993-08-03 Ventech Research Inc. Mixture of a non-covalent heterodimer complex and a basic amphiphatic peptide as cytotoxic agent
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
WO1997040679A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
CA2253937A1 (en) * 1996-05-10 1997-11-20 Phylomed Corporation Methods for oxidizing disulfide bonds using ozone
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
CA2302316A1 (en) 1997-09-15 1999-03-25 Genetic Immunity, Llc. Method of delivering genes to antigen presenting cells of the skin
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
ATE429240T1 (de) * 1999-01-29 2009-05-15 Esperanza Peptide Ltd Bukkales verabreichungssystem für proteinhaltige medikamente
WO2001042462A2 (en) * 1999-12-08 2001-06-14 National University Of Singapore Phospholipase a2 inhibitory peptides from python reticulatus
US20060045875A1 (en) * 2004-09-02 2006-03-02 Reid Paul F Method of use of crotoxin as an anti-retroviral agent
US20060234299A1 (en) * 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
US20070128179A1 (en) * 2005-11-08 2007-06-07 Ponnampalam Gopalakrishnakone Phospholipase(s) and use(s) thereof
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP

Also Published As

Publication number Publication date
US8278265B2 (en) 2012-10-02
US20080181849A1 (en) 2008-07-31
BRPI0501037B1 (pt) 2019-05-07
EP1866332A1 (en) 2007-12-19
BRPI0501037B8 (pt) 2021-07-27
WO2006096953A1 (en) 2006-09-21
EP1866332B1 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
BRPI0710485B8 (pt) composições líquidas úteis no tratamento de doenças respiratórias
EP1687283A4 (en) FOR THE DETERMINATION OF FK506 PROCEDURE AND COMPOSITION
AR066787A1 (es) Genes del citocromo p450 que confieren resistencia a los herbicidas
NO20081233L (no) Albumin fusjonsproteiner
NO20064059L (no) Albumin fusjonsproteiner
BRPI0710483B8 (pt) dispositivo compreendendo composições com fenilefrina, cloridrato de fenilefrina, bromidrato de fenilefrina, e misturas das mesmas e kits úteis para o tratamento de doenças respiratórias
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
EP1994142A4 (en) METHOD AND COMPOSITIONS FOR FAST ISOLATION OF SMALL RNA MOLECULES
EP1931806A4 (en) PKR ACTIVATION BY HYBRIDIZATION CHAIN REACTION
NO20082240L (no) GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
AU8023898A (en) Combined product associating a nucleic acid with a substance breaking up the extracellular matrix for gene therapy
BRPI0714844B8 (pt) molécula de ácido nucleico e seus usos, composição farmaceutica e complexo
WO2008030610A3 (en) Human transcriptome corresponding to human oocytes and use of said genes or the corresponding polypeptides to trans-differentiate somatic cells
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
BRPI0600199A (pt) usos de ácido pinolênico ou um seu derivado e de uma composição
BRPI0510664B8 (pt) derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios
BRPI0514124B8 (pt) anticorpos monoclonais específicos para il-4 humana, seu uso, composição farmacêutica que os comprende e polinucleotídeos
CL2007003305A1 (es) Compuestos analogos de adenosina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermdades tales como fibrosis quistica, otitis media, asma, ulcera peptica, entre otras.
Padron-Barthe et al. Conformational modification of serpins transforms leukocyte elastase inhibitor into an endonuclease involved in apoptosis
BRPI0501037A (pt) uso de crotamina, kit e composição
ATE484515T1 (de) Dna-polymerase-mischungen und mutante dna- polymerasen
EP1581054A4 (en) TREATMENT OF HSV-CONDITIONING PATHOLOGIES WITH SSDNA
UY29544A1 (es) Tratamiento de enfermedades usando un sistema mejorado de expresión regulada

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: G01N 33/68 (2010.01), C07K 14/46 (2010.01), A61K 3

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/46 (2006.01), G01N 33/68 (2006.01), A61K 3

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.